Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

ALN-S, liquid alendronate sodium trihydrate; ALN-T, alendronate sodium oral tablet; FAS, full analysis set; PPS, per-protocol set; SS, safety setBaseline characteristics of the participantsALN-S (N = 69)ALN-T (N = 63)p valueMean (or N)SD (or %)Mean (or N)SD (or %)Age (years)*62.87.564.07.70.342Height (cm)*156.95.0155.25.60.064Weight (kg)*55.47.755.57.20.923Systolic blood pressure (mmHg)*123.113.2123.614.40.839Diastolic blood pressure (mmHg)*70.011.172.710.60.162Calcium (mg/dL)*9.30.39.30.30.633Phosphorus (g/dL)*3.80.53.70.40.763Albumin (g/dL)*4.50.34.50.20.749ALP (U/L)*74.821.368.417.30.060BUN (mg/dL)*15.14.015.84.20.305Creatinine (mg/dL)*0.70.10.70.10.875Total cholesterol (mg/dL)*183.752.0186.731.20.683Parathyroid hormone (pg/mL)*40.822.538.713.60.51825-hydroxy vitamin D (ng/mL)*29.59.131.29.30.292Baseline CTX (ng/mL)*0.4670.2310.4920.2290.528Baseline PINP (ng/mL)*51.018.547.718.70.309Baseline LSBMD (g/cm2)*0.7440.0890.7280.0790.277Baseline LS T-score* − 2.40.7 − 2.50.70.526Baseline FN BMD (g/ cm2)*0.6000.1000.5770.0790.153Baseline FN T-score* − 2.10.7 − 2.20.60.295Baseline TH BMD (g/ cm2)*0.7050.0790.7020.0740.829Baseline TH T-score* − 1.40.6 − 1.40.60.693FRAX: major osteoporotic fracture (%)*10.35.211.45.40.224FRAX: hip fracture (%)*3.72.74.22.80.246Previous fracture history†2130.42031.70.871Parents’ hip fracture history†68.7914.30.312Current smoking††11.423.20.606Alcohol > 3 units/day00.000.0NAHistory of glucocorticoid††00.011.60.477History of rheumatoid arthritis00.000.0NASecondary osteoporosis††68.723.20.278ALN-S, alendronate oral solution; ALN-T, alendronate oral tablet; CTX, C-telopeptide; PINP, procollagen type 1 N-terminal propeptide; LS, lumbar spine; BMD, bone mineral density; FN, femoral neck; TH, total hip; FRAX, fracture risk assessment tool*Two-sample t-test, †chi-square test, ††Fisher’s exact test

Source: Baseline characteristics. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Randomised controlled trial.

Randomised controlled trial

Assigns participants or groups to comparison interventions by chance.

Meta-analysis unclear · Open-label reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Efficacy and safety of weekly liquid alendronate in Korean postmenopausal women with osteoporosis: a 12-month, multi-center, randomized trial

Source: Article title.

In a 12-month, multi-center, prospective, randomized, open-labeled, parallel trial conducted at two hospitals in Korea, 170 patients were randomized to alendronate solution (ALN-S) (N = 85) or alendronate tablet (ALN-T) (N = 85) groups.

Source: Abstract.

This was a 12-month, multicenter, prospective, randomized, open-label, parallel trial conducted at two hospitals in South Korea (Severance Hospital and Inha University Hospital) to compare the efficacy and safety of alendronate solution and tablets.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Efficacy and safety of weekly liquid alendronate in Korean postmenopausal women with osteoporosis: a 12-month, multi-center, randomized trial

Randomised controlled trial · Archives of Osteoporosis · 2024

Original publication title

Efficacy and safety of weekly liquid alendronate in Korean postmenopausal women with osteoporosis: a 12-month, multi-center, randomized trial

Seungjin Baek; Seong Hee Ahn; Namki Hong; Da Hea Seo; Seongbin Hong; Yumie Rhee

© The Author(s) 2024

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Liquid alendronate was non-inferior to tablet alendronate in increasing BMD in Korean postmenopausal women with osteoporosis, presenting a viable alternative when the tablet form is limited in various clinical scenarios.

An extract from the source publication. Read it in context.

At a glance

Abstract: What methods does the paper describe?

In a 12-month, multi-center, prospective, randomized, open-labeled, parallel trial conducted at two hospitals in Korea, 170 patients were randomized to alendronate solution (ALN-S) (N = 85) or alendronate tablet (ALN-T) (N = 85) groups. The bone mineral density (BMD) of the lumbar spine (LS), femoral neck (FN), and total hip (TH) was measured at baseline and after 12 months. Bone turnover markers (BTMs) were assessed at baseline, 6, and 12 months. The primary outcome was the percentage change in BMD of the LS, evaluated for non-inferiority.

Source: Methods

Abstract: Summary

This study compared liquid and tablet forms of alendronate for osteoporosis treatment. After 12 months, both forms increased bone density to a similar degree with no significant differences in side effects. New low-volume liquid alendronate is as effective as tablets, offering an alternative treatment option for postmenopausal women with osteoporosis.

Source: Summary

Abstract: Purpose/Introduction

Alendronate, despite its significant efficacy, poses challenges due to complex administration protocols and patient compliance issues, underscoring the need for various formulations. This study compared the efficacy and safety of once-weekly low-volume liquid alendronate sodium trihydrate (ALN-S), an oral solution, to once-weekly alendronate sodium (ALN-T), an oral tablet, in Korean postmenopausal women with osteoporosis.

Source: Purpose/Introduction

Abstract: Results

After 12 months, both ALN-S and ALN-T groups exhibited a significant increase in LS, FN, and TH BMD, with no significant intergroup differences (ALN-S: LS 5.0 ± 0.6%, FN 1.8 ± 0.6%, TH 2.2 ± 0.5%; ALN-T: LS 5.2 ± 0.6%, FN 1.6 ± 0.6%, TH 1.8 ± 0.5%). ALN-S was found to be non-inferior to ALN-T for BMD change at LS (treatment difference: − 0.22%, 95% CI: − 1.84 to 1.40%), excluding the predefined non-inferiority margin of − 2.29%.

Changes in BTMs did not differ significantly between groups. The frequency of adverse events was similar between groups.

Source: Results

Abstract: Conclusion

Liquid alendronate was non-inferior to tablet alendronate in increasing BMD in Korean postmenopausal women with osteoporosis, presenting a viable alternative when the tablet form is limited in various clinical scenarios.

Source: Conclusion
Authors’ abstract

Summary

This study compared liquid and tablet forms of alendronate for osteoporosis treatment. After 12 months, both forms increased bone density to a similar degree with no significant differences in side effects. New low-volume liquid alendronate is as effective as tablets, offering an alternative treatment option for postmenopausal women with osteoporosis.

Purpose/Introduction

Alendronate, despite its significant efficacy, poses challenges due to complex administration protocols and patient compliance issues, underscoring the need for various formulations. This study compared the efficacy and safety of once-weekly low-volume liquid alendronate sodium trihydrate (ALN-S), an oral solution, to once-weekly alendronate sodium (ALN-T), an oral tablet, in Korean postmenopausal women with osteoporosis.

Methods

In a 12-month, multi-center, prospective, randomized, open-labeled, parallel trial conducted at two hospitals in Korea, 170 patients were randomized to alendronate solution (ALN-S) (N = 85) or alendronate tablet (ALN-T) (N = 85) groups. The bone mineral density (BMD) of the lumbar spine (LS), femoral neck (FN), and total hip (TH) was measured at baseline and after 12 months. Bone turnover markers (BTMs) were assessed at baseline, 6, and 12 months. The primary outcome was the percentage change in BMD of the LS, evaluated for non-inferiority.

Results

After 12 months, both ALN-S and ALN-T groups exhibited a significant increase in LS, FN, and TH BMD, with no significant intergroup differences (ALN-S: LS 5.0 ± 0.6%, FN 1.8 ± 0.6%, TH 2.2 ± 0.5%; ALN-T: LS 5.2 ± 0.6%, FN 1.6 ± 0.6%, TH 1.8 ± 0.5%). ALN-S was found to be non-inferior to ALN-T for BMD change at LS (treatment difference: − 0.22%, 95% CI: − 1.84 to 1.40%), excluding the predefined non-inferiority margin of − 2.29%.

Changes in BTMs did not differ significantly between groups. The frequency of adverse events was similar between groups.

Conclusion

Liquid alendronate was non-inferior to tablet alendronate in increasing BMD in Korean postmenopausal women with osteoporosis, presenting a viable alternative when the tablet form is limited in various clinical scenarios.

Clinical trial registration

The trial was registered with ClinicalTrials.gov (NCT05387200).

Publication and source details

Original title: Efficacy and safety of weekly liquid alendronate in Korean postmenopausal women with osteoporosis: a 12-month, multi-center, randomized trial

Seungjin Baek; Seong Hee Ahn; Namki Hong; Da Hea Seo; Seongbin Hong; Yumie Rhee

Archives of Osteoporosis · 2024

© The Author(s) 20242024https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.dongkook pharmaceutical Co., Ltd.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T08:17:21.369673+00:00

DOI: 10.1007/s11657-024-01480-6 · PMC11599418